|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
|
Oct 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
|
May 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
|
Feb 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
|
Feb 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Expression of nucleoside metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
|
Nov 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Application of the International Prognostic Scoring System-Revised (IPSS-R) in Therapy-related Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia.
|
Jun 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
|
Sep 2014
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
